Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellectar BiosciencesCLRB 23 EV-to-OCF is -0.78 as of Aug. 11, 2026. GuruFocus rates CLRB with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 1,406 Biotechnology companies, Cellectar Biosciences ranks worse than 65.36% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cellectar Biosciences's Enterprise Value is $14.48 Mil.
Cellectar Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-18.58 Mil. Therefore, Cellectar Biosciences's EV-to-OCF for today is -0.78.
The historical rank and industry rank for Cellectar Biosciences's EV-to-OCF or its related term are showing as below:
CLRB'
s EV-to-OCF Range Over the Past 10 Years
Min: -0.79 Med: 0 Max: -0.76
Current: -0.78
During the past 13 years, the highest EV-to-OCF of Cellectar Biosciences was -0.76. The lowest was -0.79. And the median was .
CLRB's EV-to-OCF is ranked worse than 65.36% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs CLRB: -0.78
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cellectar Biosciences's PE Ratio (TTM) for today is calculated as:
Cellectar Biosciences's share price for today is $2.60.
Cellectar Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.379.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cellectar Biosciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellectar Biosciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cellectar Biosciences's EV-to-OCF falls into.
Cellectar Biosciences's current Enterprise Value is $14.48 Mil.
Cellectar Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellectar Biosciences (CLRB) has a EV-to-OCF of -0.78 as of Aug. 11, 2026. According to the industry distribution chart, Cellectar Biosciences ranks #919 out of 1406 companies in the Biotechnology industry, placing it in the top 65.4%.
Is Cellectar Biosciences' EV-to-OCF too high?
Cellectar Biosciences' current EV-to-OCF is -0.78. Based on the distribution chart, Cellectar Biosciences ranks #919 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cellectar Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Cellectar Biosciences' EV-to-OCF compare to DARE and NEUP?
According to the Biotechnology industry distribution chart, Cellectar Biosciences ranks #919 out of 1406 companies for EV-to-OCF. This places Cellectar Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Cellectar Biosciences's current EV-to-OCF is -0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectar Biosciences stock overvalued right now?
Cellectar Biosciences (CLRB) has a current EV-to-OCF of -0.78. The current EV-to-OCF is -0.78. Cellectar Biosciences' overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cellectar Biosciences (CLRB), the current EV-to-OCF is -0.78 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
23GF Score
Get the complete analysis for CLRB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLRB has been successfully added to your 
